Vitiligo is a chronic depigmenting disorder that imposes a substantial psychological, social, and economic burden, extending beyond its physical manifestations. This narrative review synthesizes and critically evaluates current evidence on the determinants of quality of life impairment among individuals with vitiligo. A review of the published literature was conducted, focusing on studies evaluating health-related quality of life, psychosocial outcomes, stigma, psychiatric comorbidities, and validated quality of life assessment instruments in patients with vitiligo. Evidence from systematic reviews, cohort studies, cross-sectional analyses, and instrument validation studies was examined to identify the clinical, demographic, and sociocultural factors associated with disease burden. Across studies, vitiligo was consistently associated with significant impairment in psychological and social domains of quality of life. Disease visibility, particularly involvement of the face or genital regions; greater body surface area involvement; active disease progression; and longer disease duration emerged as key clinical factors associated with worse outcomes. Several demographic and sociocultural characteristics, including female sex, younger age, darker skin phototype, unmarried status, and residence in highly stigmatizing cultural environments, were also associated with greater quality of life impairment. Depression and anxiety were more frequently reported in individuals with vitiligo than in the general population, with pediatric and adolescent patients demonstrating particularly high vulnerability. Although dermatology-specific instruments such as the Dermatology Life Quality Index are commonly used in research and clinical practice, vitiligo-specific tools may more accurately capture stigma, social participation limitations, and disease-specific psychosocial impact. Overall, the available evidence indicates that vitiligo imposes a profound psychosocial burden that often exceeds the objective clinical severity of depigmentation. Quality of life impairment appears to be driven primarily by lesion visibility, sociocultural context, and psychological comorbidity rather than symptom severity alone. These findings underscore the importance of incorporating validated quality of life assessment tools into routine clinical care, screening for psychiatric comorbidities, and adopting culturally sensitive and patient-centered approaches to vitiligo management.
Costa et al. (Fri,) studied this question.